Previous 10 | Next 10 |
Provention Bio is focused on slowing down, or actually preventing in some cases, the onset of autoimmune conditions. Provention's first therapeutic, teplizumab, looks set for approval in mid-2021 in what could be the first of several indicated populations. Provention looks like a ...
Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference PR Newswire RED BANK, N.J. , Jan. 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-medi...
Provention Bio ([[PRVB]] +6.7%) has filed the FDA marketing application for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals.The FDA has granted a priority review for the diabetes drug with action date set at July 2. The company says if approved, ...
Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals -FDA sets PDUFA goal date of July 2, 2021- -If approved, teplizumab will be the...
Provention Bio Announces Addition to NASDAQ Biotechnology Index PR Newswire RED BANK, N.J. , Dec. 21, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, toda...
Provention Bio (PRVB) has initiated PROVENT (PROtocol for coxsackievirus VaccinE in healthy voluNTeers), a first-in-human study of its polyvalent inactivated coxsackievirus B ((CVB)) vaccine candidate, PRV-101.PRV-101 is being developed for the prevention of acute CVB infection and the potent...
Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 RED BANK, N.J. , Dec. 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-me...
JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) Detection NEW YORK and RED BANK, N.J. , Dec. 8, 2020 /PRNewswire/ -- On the heels of National Diabetes Awareness Month, JDRF, the leading global funder of type 1 diabetes (T1D) research,...
Provention Bio to Present at the Stifel Virtual Healthcare Conference PR Newswire RED BANK, N.J., Nov. 11, 2020 RED BANK, N.J. , Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting...
Image source: The Motley Fool. Provention Bio, Inc (NASDAQ: PRVB) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 p.m. ET Operator Continue reading For further details see: Provention Bio, Inc (PRVB) Q3 2020 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Provention Bio, Inc. (NASDAQ: PRVB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 3.14% on the day to $24.99. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and comme...
2023-04-06 11:29:16 ET What Are Penny Stocks? The market for penny stocks has continued growing over the last few years. But what are these stocks in the first place? The general definition of penny stocks includes shares of companies trading below $5. Making money with penny st...
NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale t...